Budesonide/Formoterol Fumarate

Brand name: Symbicort

Rank #22 of 500 drugs by total cost

Data: CMS Medicare Part D, 2023 (most current available) · Updated March 2026

$759.4M

Total Cost

Share:

1,452,561

Total Claims

$759.4M

Total Cost

45,441

Prescribers

$523

Cost per Claim

223,970

Beneficiaries

1,984,484

30-Day Fills

$17K

Avg Cost/Provider

32

Avg Claims/Provider

Share of Medicare Part D Spending

0.28%

of total Medicare Part D spending

$759.4M of $275.65B

Top Prescribers by Cost

Top 10 prescribers of $759.4M total

🔎 Data Overview

📊

Ranked #22 out of 500 drugs tracked by total cost. Budesonide/Formoterol Fumarate represents a significant portion of Medicare drug spending.

Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.

Top Prescribers of Budesonide/Formoterol Fumarate

#ProviderSpecialtyLocationClaimsCost
1Jorge Sanchez-MasiquesPulmonary DiseaseMiami, FL5,055$2.1M
2Jahaira Serrano DominguezPulmonary DiseaseArecibo, PR2,361$925K
3Jorge Sanchez-MasiquesPulmonary DiseaseMiami, FL2,961$790K
4Mohammad-Ali El-HarakehInternal MedicinePrescott, AZ831$536K
5Vishnu PatelInternal MedicinePrinceton, WV868$441K
6Jason KarpPulmonary DiseaseLake Success, NY517$385K
7Venkata DoddaPulmonary DiseaseBloomington, IL510$374K
8Fateh AhmedPulmonary DiseaseToledo, OH654$374K
9George MartinAllergy/ ImmunologyWynnewood, PA507$368K
10Richard DelucaPulmonary DiseaseBronx, NY448$355K
11Bradley ChippsPulmonary DiseaseSacramento, CA514$342K
12Jon MichelPulmonary DiseasePeoria, IL571$331K
13Mohammad ChaudhryInternal MedicineUnion City, NJ689$328K
14Ernesto MejiaPulmonary DiseaseMorristown, TN554$317K
15Hazen TuckPulmonary DiseaseJanesville, WI568$309K

Top prescribers ranked by total cost for this drug in 2023.

Related Drugs by Cost

#DrugTotal CostClaims
19Ustekinumab (Stelara)$852.3M31,974
20Paliperidone Palmitate (Invega Sustenna)$832.3M252,388
21Insulin Aspart (Novolog Flexpen)$831.6M958,823
22Budesonide/Formoterol Fumarate (Symbicort)$759.4M1,452,561
23Palbociclib (Ibrance)$755.1M48,329
24Nintedanib Esylate (Ofev)$703.7M53,928
25Ruxolitinib Phosphate (Jakafi)$698.1M46,655

Related Analysis

Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology